Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | PRKCG | P05129 | 1/20 | 0.47 |
| ▸ | PRKCB | P05771 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | PRKCH | P24723 | 1/20 | 0.47 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.47 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.47 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7149906 | 1.00 | HSD17B10 (0.70) | HSD17B10USP2HTTSPHK1TDP1 | |
| SCHEMBL535931 | 1.00 | HSD17B10 (0.70) | HSD17B10USP2HTTSPHK1TDP1 | |
| SCHEMBL9637036 | 0.98 | HSD17B10 (0.67) | HSD17B10USP2HTTSPHK1TDP1 | |
| SCHEMBL1091934 | 0.98 | HSD17B10 (0.67) | HSD17B10USP2HTTSPHK1TDP1 | |
| SCHEMBL7661581 | 0.98 | HSD17B10 (0.67) | HSD17B10USP2HTTSPHK1TDP1 | |
| SCHEMBL10745894 | 0.98 | HSD17B10 (0.67) | HSD17B10USP2HTTSPHK1TDP1 | |
| SCHEMBL7549303 | 0.98 | HSD17B10 (0.67) | HSD17B10USP2HTTSPHK1TDP1 | |
| SCHEMBL15070143 | 0.98 | HSD17B10 (0.67) | HSD17B10USP2HTTSPHK1TDP1 | |
| SCHEMBL21046009 | 0.98 | HSD17B10 (0.67) | HSD17B10USP2HTTSPHK1TDP1 | |
| SCHEMBL186489 | 0.98 | HSD17B10 (0.67) | HSD17B10USP2HTTSPHK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3787402-A1 | EMULSIFIABLE CONCENTRATES | Dow Global Technologies, LLC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-6384228-B2 | EPIBATIDINE; ANALGESICS; ANIMAL EXTRACTS | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| US-20020010339-A1 | METHOD FOR SYNTHESIS OF HALOPYRIDYL-ACYCLOPENTANE DERIVATIVE AND INTERMEDIATE THEREOF | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2002-01-24 | — | — | US | disclosed |
| EP-0301587-B1 | LIQUID CRYSTAL COMPOUNDS AND INTERMEDIATES THEREOF | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1992-07-15 | — | — | EP | disclosed |
| US-5114615-A | Compounds for optical apparatus | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1992-05-19 | — | — | US | disclosed |
| EP-0301587-A1 | Liquid crystal compounds and intermediates thereof | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1989-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010339-A1 | METHOD FOR SYNTHESIS OF HALOPYRIDYL-ACYCLOPENTANE DERIVATIVE AND INTERMEDIATE THEREOF | DHPS, ALAD, HAAO | HSD17B10 154/4885USP2 2560/4885HTT 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.